Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
Postponement and Re-scheduling of Annual General Meeting
Biodexa issues letter to Shareholders
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
Preliminary Results for the Year Ended 31 December 2025
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Scheduled to Reverse Split on Monday, April 6th
ADR Ratio Change
Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis
Biodexa Announces Pricing of $10 Million Public Offering
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
Interim results for the six months ended June 30, 2025
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
ADR Ratio Change Effective
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market
ADR Ratio Change
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Results of Annual General Meeting
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
Result of General Meeting
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Shareholder Update
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
Result of General Meeting
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock
Notice of General Meeting
Preliminary Results for the Year Ended 31 December 2024
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status